2.88

3.97% 0.11

Pre-market: 3.02 0.14 +4.86%

Orchestra Biomed Holdings Inc (OBIO)

Overview News Price History Discussions Forecast

Orchestra Biomed Holdings Inc stock is traded at $2.88, with a volume of 116.08K. It is up +3.97% in the last 24 hours and down -8.86% over the past month. Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Previous Close:

$2.77

Open:

$2.81

24h Volume:

116.08K

Relative Volume:

0.30

Market Cap:

$127.96M

Revenue:

$2.76M

Net Income/Loss:

$-49.12M

P/E Ratio:

-1.92

EPS:

-1.5

Net Cash Flow:

$-46.21M

1W Performance:

-6.80%

1M Performance:

-8.86%

6M Performance:

-46.47%

1Y Performance:

-61.29%

1-Day Range:

$2.79

$2.915

1-Week Range:

$2.60

$3.29

52-Week Range:

$2.37

$8.8699

Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile

Name

Orchestra Biomed Holdings Inc

Sector

Healthcare (1166)

Industry

Biotechnology (655)

Phone

646-343-9298

Address

150 UNION SQUARE DRIVE, NEW HOPE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

OBIO's Discussions on Twitter

Compare OBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OBIO Orchestra Biomed Holdings Inc	2.88	127.96M	2.76M	-49.12M	-46.21M	-1.50
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-25	Initiated	BTIG Research	Buy
Jan-02-25	Initiated	Barclays	Overweight
Aug-22-24	Initiated	H.C. Wainwright	Buy
Jul-25-24	Initiated	B. Riley Securities	Buy
Jan-19-24	Initiated	Jefferies	Buy
Feb-24-23	Initiated	Piper Sandler	Overweight
Feb-07-23	Initiated	Chardan Capital Markets	Buy

View All

Orchestra Biomed Holdings Inc Stock (OBIO) Latest News

Jun 18, 2025

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built - GlobeNewswire

Jun 18, 2025

Jun 14, 2025

Millennium Management LLC Makes New Investment in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World

Jun 14, 2025

Jun 12, 2025

Citadel Advisors LLC Sells 7,836 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World

Jun 12, 2025

Jun 11, 2025

(OBIO) Trading Advice - news.stocktradersdaily.com

Jun 11, 2025

Jun 02, 2025

Orchestra Biomed Reports Increased Losses Amid Revenue Growth - TipRanks

Jun 02, 2025

May 30, 2025

B. Riley Cuts Price Target on Orchestra BioMed Holdings to $12 From $15, Keeps Buy Rating - marketscreener.com

May 30, 2025

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Stake Increased by Northern Trust Corp - Defense World

May 30, 2025

May 28, 2025

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships - Seeking Alpha

May 28, 2025

May 21, 2025

Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MSN

May 21, 2025

May 19, 2025

How To Trade (OBIO) - news.stocktradersdaily.com

May 19, 2025

The Manufacturers Life Insurance Company Raises Position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World

May 19, 2025

May 18, 2025

FY2026 Earnings Estimate for OBIO Issued By Chardan Capital - Defense World

May 18, 2025

May 15, 2025

Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation - MSN

May 15, 2025

May 14, 2025